dipyridamole has been researched along with hydroxychloroquine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (86.36) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (4.55) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Mustard, JF; Packham, MA | 1 |
| Kher, A; Toulemonde, F | 1 |
| Hirsh, J; Turpie, AG | 1 |
| Huguier, M; Uhl, JF | 1 |
| Hirsh, J | 1 |
| Dettori, AG; Pini, M; Quintavalla, R | 1 |
| Latour, JG | 1 |
| Hladovec, J | 1 |
| Dechavanne, M; Follea, G; Trzeciak, MC | 1 |
| Gent, M; Genton, E; Harker, LA; Hirsh, J | 2 |
| Gallus, AS; Hirsh, J | 1 |
| Gent, M; Genton, E; Hirsh, J | 1 |
| Didisheim, P; Fuster, V; Kazmier, FJ | 1 |
| Bounameaux, Y | 1 |
| Birgens, HS; Hansen, MS | 1 |
| Bouchier-Hayes, D | 1 |
| Verstraete, M | 1 |
| Turpie, AG | 1 |
| Cui, J; Huang, YY; Li, X; Li, Z; Lin, Y; Liu, H; Liu, R; Luo, HB; Wang, X; Wu, D; Wu, Y; Xu, X; Yu, K; Zhan, CG; Zhang, L; Zhang, Y; Zhou, L | 1 |
| Ekins, S; Puhl, AC; Urbina, F | 1 |
14 review(s) available for dipyridamole and hydroxychloroquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical pharmacology of platelets.
Topics: Adenosine Diphosphate; Aspirin; Blood Coagulation; Blood Platelets; Cell Membrane; Clofibrate; Cyproheptadine; Dipyridamole; Drug Therapy, Combination; Furosemide; Halofenate; Heparin; Humans; Hydrocortisone; Hydroxychloroquine; Methylprednisolone; Penicillin G; Platelet Aggregation; Propranolol; Prostaglandins; Sulfinpyrazone; Vitamin E | 1977 |
[Prevention of postoperative thrombo-embolic complications. The principal methods, other than low-dose heparin].
Topics: Anticoagulants; Dextrans; Dipyridamole; Femoral Neck Fractures; Heparin; Hip Joint; Humans; Hydroxychloroquine; Joint Prosthesis; Postoperative Complications; Risk; Thromboembolism; Thrombophlebitis; Vitamin K | 1977 |
Platelet suppressive therapy.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dipyridamole; Fibrinolytic Agents; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Hydroxychloroquine; Sulfinpyrazone; Thrombophlebitis; Thrombosis | 1978 |
[Prevention of thrombosis and embolism in digestive surgery].
Topics: Anticoagulants; Aspirin; Coumarins; Dextrans; Digestive System Surgical Procedures; Dipyridamole; Heparin; Humans; Hydroxychloroquine; Postoperative Complications; Prospective Studies; Pulmonary Embolism; Random Allocation; Thromboembolism; Thrombophlebitis | 1979 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Coronary Disease; Dipyridamole; Double-Blind Method; Female; Heart Valve Prosthesis; Humans; Hydroxychloroquine; Ischemic Attack, Transient; Male; Middle Aged; Postoperative Complications; Random Allocation; Sulfinpyrazone; Thromboembolism; Thrombosis | 1978 |
[Treatment with antiplatelet drugs. Current status of knowledge].
Topics: Aspirin; Blood Platelet Disorders; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dextrans; Dipyridamole; Fibrinolytic Agents; Heart Valve Prosthesis; Humans; Hydroxychloroquine; Platelet Aggregation; Postoperative Complications; Sulfinpyrazone; Thromboembolism | 1979 |
[Clinical prevention of thrombosis by antiplatelet agents].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Humans; Hydroxychloroquine; Sulfinpyrazone; Thrombosis | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Coronary Disease; Dipyridamole; Drug Combinations; Female; Heart Valve Prosthesis; Humans; Hydroxychloroquine; Kidney Diseases; Kidneys, Artificial; Male; Silicone Elastomers; Sulfinpyrazone; Thromboembolism; Thrombosis; Vascular Diseases | 1975 |
Antithrombotic drugs: part II.
Topics: Anabolic Agents; Ancrod; Animals; Aspirin; Blood Platelets; Clofibrate; Dextrans; Dipyridamole; Fibrinolytic Agents; Humans; Hydroxychloroquine; Myocardial Infarction; Plasminogen Activators; Streptokinase; Sulfinpyrazone; Thromboembolism; Thrombophlebitis; Urokinase-Type Plasminogen Activator | 1976 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamole; Fibrinogen; Heart Valve Prosthesis; Humans; Hydroxychloroquine; Iodine Radioisotopes; Molecular Weight; Myocardial Infarction; Phlebography; Renal Dialysis; Sulfinpyrazone; Thromboembolism; Thrombophlebitis; Thrombosis | 1974 |
[Critical evaluation of the usefulness of drugs inhibiting platelet function in the prevention of postoperative deep venous thrombosis and in ischemic cardiopathy].
Topics: Anticoagulants; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Fibrinolytic Agents; Flurbiprofen; Humans; Hydroxychloroquine; Lidocaine; Platelet Aggregation; Postoperative Complications; Pulmonary Embolism; Sulfinpyrazone; Thromboembolism; Thrombophlebitis | 1980 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Heart Diseases; Humans; Hydroxychloroquine; Neoplasms; Sulfinpyrazone; Thromboembolism; Thrombosis | 1982 |
Recent advances in drug repurposing using machine learning.
Topics: Alzheimer Disease; Antineoplastic Agents; Antiviral Agents; Clemastine; Computational Biology; COVID-19 Drug Treatment; Dipyridamole; Drug Repositioning; Humans; Hydroxychloroquine; Lenalidomide; Machine Learning; Neoplasms; Neuroprotective Agents; Piperazines; Piperidines; Protein Kinase Inhibitors | 2021 |
5 trial(s) available for dipyridamole and hydroxychloroquine
| Article | Year |
|---|---|
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Coronary Disease; Dipyridamole; Double-Blind Method; Female; Heart Valve Prosthesis; Humans; Hydroxychloroquine; Ischemic Attack, Transient; Male; Middle Aged; Postoperative Complications; Random Allocation; Sulfinpyrazone; Thromboembolism; Thrombosis | 1978 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Coronary Disease; Dipyridamole; Drug Combinations; Female; Heart Valve Prosthesis; Humans; Hydroxychloroquine; Kidney Diseases; Kidneys, Artificial; Male; Silicone Elastomers; Sulfinpyrazone; Thromboembolism; Thrombosis; Vascular Diseases | 1975 |
The current status of platelet suppressive drugs in the treatment of thrombosis.
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cardiac Catheterization; Cell Survival; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Dipyridamole; Heart Valve Prosthesis; Humans; Hydroxychloroquine; Myocardial Infarction; Postoperative Complications; Renal Dialysis; Sulfinpyrazone; Thrombocytosis; Thromboembolism | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts).
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; Fibrinolytic Agents; Humans; Hydroxychloroquine; Postoperative Complications; Pulmonary Embolism; Sulfinpyrazone; Thromboembolism; Thrombophlebitis; Thrombosis | 1975 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Heart Diseases; Humans; Hydroxychloroquine; Neoplasms; Sulfinpyrazone; Thromboembolism; Thrombosis | 1982 |
6 other study(ies) available for dipyridamole and hydroxychloroquine
| Article | Year |
|---|---|
Is the antithrombotic activity of "antiplatelet" drugs based on protection of endothelium?
Topics: Animals; Aspirin; Citrates; Clofibrate; Dipyridamole; Endothelium; Female; Hydroxychloroquine; Platelet Aggregation; Rats; Sulfinpyrazone | 1979 |
[Antiplatelet drugs (author's transl)].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Female; Humans; Hydroxychloroquine; Ischemic Attack, Transient; Male; Myocardial Infarction; Nicergoline; Platelet Aggregation; Sulfinpyrazone; Thrombosis | 1979 |
[Clinical use of anti-aggregative agents].
Topics: Aspirin; Dipyridamole; Humans; Hydroxychloroquine; Platelet Adhesiveness; Thromboembolism; Thrombophlebitis; Thrombosis | 1973 |
[Prevention of thrombosis by thrombocyte inhibitors. 1. Cell regulation mechanisms and pharmacological modification].
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Cyclic AMP; Dextrans; Dipyridamole; Humans; Hydroxychloroquine; Indomethacin; Platelet Aggregation; Prostaglandins; Sulfinpyrazone; Thrombosis; Thromboxane A2 | 1980 |
Drugs in the treatment of thrombo-embolic disease--part I.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Carotid Artery Diseases; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Dose-Response Relationship, Drug; Gastrointestinal Hemorrhage; Heart Valve Prosthesis; Humans; Hydroxychloroquine; Sulfinpyrazone; Thromboembolism; Thrombophlebitis | 1983 |
Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Dipyridamole; Drug Repositioning; Humans; Hydroxychloroquine; Molecular Docking Simulation; Molecular Structure; Pandemics; Pneumonia, Viral; Protease Inhibitors; SARS-CoV-2; Viral Nonstructural Proteins | 2020 |